The U.S. Patent and Trademark Office (USPTO) have issued U.S. Patent No. 7,132,570 (the '570 patent) covering a novel polymorphic form of armodafinil to Cephalon, Inc. (Nasdaq: CEPH).
Armodafinil is the active pharmaceutical ingredient in NUVIGIL™ (armodafinil) Tablets -- currently pending approval with the USFDA.
According to Dr. Jeffry Vaught, Executive Vice President and President of Research & Development:
"Our scientists have discovered several novel polymorphs associated with armodafinil.
Significantly, we believe polymorphic Form I is the most stable crystalline form of these, is present in the formulation that we expect to bring to market, and is very likely to be present in any other formulation of armodafinil that may be developed.
We believe this patent will provide strong protection for NUVIGIL."
The said US patent, expiring on Dec. 18, 2023, specifically claims compositions of matter of the Form I polymorph of armodafinil, as well as pharmaceutical formulations and methods of manufacturing.
Read more from the press release.
.jpg)
Comment Preview